Insulin resistance and altered glucose transporter 4 expression in experimental uremia

Kidney International

Volumn 75, Issue 7, 2009, Pages 711-718

  Aksentijević, Dunja ^a,d   Bhandari, Sunil ^b   Seymour, Anne Marie L ^a,c  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

GLUT4 expression; Heart disease; Insulin resistance; Left ventricular hypertrophy; Uremia

Indexed keywords

GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4;

ANEMIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEART LEFT VENTRICLE HYPERTROPHY; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; MALE; NEPHRON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPRAGUE DAWLEY RAT; UREMIA;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; HEART VENTRICLES; INSULIN RESISTANCE; MALE; RATS; RATS, SPRAGUE-DAWLEY; UREMIA;

EID: 62349109212     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.691     Document Type: Article

References (51)

1. Levey AS, Andreoli SP, DuBose T et al. Chronic kidney disease: common, harmful and treatable - World Kidney Day 2007. Am J Nephrol 2007; 27: 108-112.
2. Kaysen GA. Disorders in high-density metabolism with insulin resistance and chronic kidney disease. J Ren Nutr 2007; 17: 4-8.
3. Stefanovic V, Nesic V, Stojimirovic B. Treatment of insulin resistance in uremia. Int J Artif Organs 2003; 26: 100-104.
4. de Vinuesa SG, Goicoechea M, Kanter J et al. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. J Am Soc Nephrol 2006; 17: S206-S212.
5. Chen J, Muntner P, Hamm LL et al. Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol 2003; 14: 469-477.
6. Shinohara K, Shoji T, Emoto M et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
7. Amann K, Ritz E. The heart in renal failure:morphological changes of the myocardium-new insights. J Clin Basic Cardiol 2001; 4: 109-113.
8. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005; 85: 1093-1129.
9. Weinberg EO, Thienelt CD, Lorell BH. Pretranslational regulation of glucose transporter isoform expression in hearts with pressure-overload left ventricular hypertophy. Circulation 1995; 92: I-385.
10. Paternostro G, Camici PG, Lammerstma AA et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 1996; 98: 2094-2099.
11. Paternostro G, Pagano D, Gnecchi-Ruscone T et al. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 1999; 42: 246-253.
12. Young LH, Renfu Y, Russell R et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997; 95: 415-422.
13. Slot JW, Geuze HJ, Gigengack S et al. Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci USA 1991; 88: 7815-7819.
14. Pessin JE, Thurmond DC, Elmendorf JS et al. Molecular basis of insulin-stimulated GLUT4 vesicle trafficking. Location! Location! Location!. J Biol Chem 1999; 274: 2593-2596.
15. Paternostro G, Clarke K, Heath J et al. Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart. Cardiovasc Res 1995; 30: 205-211.
16. Garvey WT, Maianu L, Zhu JH et al. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 1998; 101: 2377-2386.
17. Cefalu WT. Insulin resistance: cellular and clinical concepts. Exp Biol Med (Maywood) 2001; 226: 13-26.
18. Reddy V, Bhandari S, Seymour AM. Myocardial function, energy provision, and carnitine deficiency in experimental uremia. J Am Soc Nephrol 2007; 18: 84-92.
19. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470.
20. Velliquette RA, Koletsky RJ, Ernsberger P. Plasma glucagon and free fatty acid responses to a glucose load in the obese spontaneous hypertensive rat (SHROB) model of metabolic syndrome X. Exp Biol Med (Maywood) 2002; 227: 164-170.
21. Cianciaruso B, Sacca L, Terracciano V et al. Insulin metabolism in acute renal failure. Kidney Int 1987; 22: S109-S112.
22. Rubenstein AH, Mako ME, Horwitz DL. Insulin and the kidney. Nephron 1975; 15: 306-326.
23. Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 53: 1343-1347.
24. Becker B, Kronenberg F, Kielstein JT et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol 2005; 16: 1091-1098.
25. Brozinick Jr JT, Yaspelkis III BB, Wilson CM et al. Glucose transport and GLUT4 protein distribution in skeletal muscle of GLUT4 transgenic mice. Biochem J 1996; 313(Part 1): 133-140.
26. Alkhateeb H, Chabowski A, Glatz JF et al. Two phases of palmitate-induced insulin resistance in skeletal muscle: impaired GLUT4 translocation is followed by a reduced GLUT4 intrinsic activity. Am J Physiol 2007; 293: E783-E793.
27. Baxter GF. The natriuretic peptides. Basic Res Cardiol 2004; 99: 71-75.
28. Rockman HA, Wachhorst SP, Mao L et al. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994; 266: H2468-H2475.
29. Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000; 36: S24-S30.
30. Kraus LM, Traxinger R, Kraus AP. Uremia and insulin resistance: N-carbamoyl-asparagine decreases insulin-sensitive glucose uptake in rat adipocytes. Kidney Int 2004; 65: 881-887.
31. Buse MG. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol 2006; 290: E1-E8.
32. Ashford D, Bhandari S, Bulmer K et al. Alterations in levels of O-linked N-acetylglucosamine modified proteins in the uraemic heart. J Mol Cell Cardiol 2007; 42: s58.
33. Aksentijevic D, Bhandari S, Seymour AM. The effects of increased calcium on myocardial function in experimental uraemia. Cardiovasc Drugs Ther 2006; 20: 395.
34. DeFronzo RA, Alvestrand A, Smith D et al. Insulin resistance in uremia. J Clin Invest 1981; 67: 563-568.
35. Doehner W, von Haehling S, Anker SD. Insulin resistance in chronic heart failure. J Am Coll Cardiol 2008; 52: 239; author reply 239-240.
36. Jefferson LS, Li JB, Rannels SR. Regulation by insulin of amino acid release and protein turnover in the perfused rat hemicorpus. J Biol Chem 1977; 252: 1476-1483.
37. Ritz E. Renal dysfunction: a novel indicator and potential promoter of cardiovascular risk. Clin Med 2003; 3: 357-360.
38. Hidvegi T, Szatmari F, Hetyesi K et al. Intima-media thickness of the carotid arteries in subjects with hyperinsulinaemia (insulin resistance). Diabetes Nutr Metab 2003; 16: 139-144.
39. Ishizaka N, Ishizaka Y, Takahashi E et al. Association between insulin resistance and carotid arteriosclerosis in subjects with normal fasting glucose and normal glucose tolerance. Arterioscler Thromb Vasc Biol 2003; 23: 295-301.
40. Yanase M, Takatsu F, Tagawa T et al. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J 2004; 68: 47-52.
41. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
42. Yin J, Gao Z, Liu D et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol 2008; 294: E148-E156.
43. Hsieh PS, Hong LZ. Augmentation of nitric oxide is crucial for the time-dependent effects of rosiglitazone on blood pressure and baroreflex function in rats. J Hypertens 2008; 26: 83-92.
44. Sample J, Cleland JG, Seymour AM. Metabolic remodeling in the aging heart. J Mol Cell Cardiol 2006; 40: 56-63.
45. Smolenski RT, Suitters A, Yacoub MH. Adenine nucleotide catabolism and adenosine formation in isolated human cardiomyocytes. J Mol Cell Cardiol 1992; 24: 91-96.
46. Santalucia T, Camps M, Castello A et al. Developmental regulation of GLUT-1 (erythroid/Hep G2) and GLUT-4 (muscle/fat) glucose transporter expression in rat heart, skeletal muscle, and brown adipose tissue. Endocrinology 1992; 130: 837-846.
47. Allard MF, Wambolt RB, Longnus SL et al. Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am J Physiol 2000; 279: E487-E493.
48. Latif N, Baker CS, Dunn MJ et al. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 1993; 22: 1378-1384.
49. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
50. Young LH, Renfu Y, Russell R et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997; 95: 415-422.
51. Rosenblatt-Velin N, Lerch R, Papageorgiou I et al. Insulin resistance in adult cardiomyocytes undergoing dedifferentiation: role of GLUT4 expression and translocation. FASEB J 2004; 18: 872-874.